All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

The EMA grants PQR309 Orphan Drug Designation for Diffuse Large B-Cell Lymphoma

By Terri Penfold

Share:

May 4, 2017


On 27th April 2017, the European Medicines Agency (EMA) granted Orphan Drug Designation status to PQR309 for the treatment of patients with DLBCL.

PIQUR Therapeutics AG’s PQR309 is an oral, brain-penetrant, dual inhibitor of the PI3K/mTOR pathway. It can cross the blood-brain barrier, making it an attractive choice in treating malignant diseases involving the brain.

PQR309 has shown pre-clinical activity in various tumor models, as well as clinical activity in phase I and II studies. The dual PI3K/mTOR pathway inhibitor is currently being investigated in a phase I/II trial (NCT02249429) and a phase II trial (NCT03127020) in R/R lymphoma, as well as two phase II trials in R/R PCNSL (NCT02669511; NCT03120000).

Currently, PQR309 already holds an Orphan Drug Designation for patients with Primary Central Nervous System Lymphoma (PCNSL), granted by the U.S. Food and Drug Administration (FDA) in December 2016.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?